Marker Therapeutics, Inc. (MRKR) Stock Analysis & Investment Frameworks
Marker Therapeutics, Inc. (MRKR) stock analysis on Invetso. Review Marker Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Marker Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Marker Therapeutics, Inc. Key Financial Metrics
- Market Cap: $14.89M
- Revenue: $N/A
- ROE: -56.96%
- ROIC: -87.91%
- Dividend Yield: N/A
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
Marker Therapeutics, Inc. Investment Frameworks
Invetso analyzes Marker Therapeutics, Inc. (MRKR) across the following frameworks:
- Marker Therapeutics, Inc. 10Y Growth Potential
- Marker Therapeutics, Inc. Scenario Analysis
- Marker Therapeutics, Inc. Risks & Opportunities
- Marker Therapeutics, Inc. Economic Moat
- Marker Therapeutics, Inc. Business Model
- Marker Therapeutics, Inc. Management
- Marker Therapeutics, Inc. SWOT Analysis
- Marker Therapeutics, Inc. Porter's 5 Forces
- Marker Therapeutics, Inc. PESTLE Analysis
- Marker Therapeutics, Inc. ESG Analysis